Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0000950170-21-001471
Filing Date
2021-08-16
Accepted
2021-08-16 08:01:27
Documents
68
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q/A verv-20210630.htm   iXBRL 10-Q/A 2675927
2 EX-31.3 verv-20210630ex31_3.htm EX-31.3 15787
3 EX-31.4 verv-20210630ex31_4.htm EX-31.4 15792
4 EX-32.3 verv-20210630ex32_3.htm EX-32.3 10619
5 EX-32.4 verv-20210630ex32_4.htm EX-32.4 10618
  Complete submission text file 0000950170-21-001471.txt   8189143

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT verv-20210630_pre.xml EX-101.PRE 316913
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT verv-20210630_cal.xml EX-101.CAL 35460
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT verv-20210630_lab.xml EX-101.LAB 419795
9 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT verv-20210630.xsd EX-101.SCH 51887
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT verv-20210630_def.xml EX-101.DEF 214202
11 EXTRACTED XBRL INSTANCE DOCUMENT verv-20210630_htm.xml XML 1360734
Mailing Address 500 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Business Address 500 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 (978) 501-3026
Verve Therapeutics, Inc. (Filer) CIK: 0001840574 (see all company filings)

EIN.: 824800132 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q/A | Act: 34 | File No.: 001-40489 | Film No.: 211174607
SIC: 2834 Pharmaceutical Preparations